Athersys

Athersys Capital Expenditures

Delisted·Oct 1, 2026

The Capital Expenditures (CapEx) of Athersys (ATHXQ) as of Nov 20, 2026 is -397,000.00 USD. In the previous year, Capital Expenditures (CapEx) was -1.36 M USD — a change of -70.81% (higher).

Capital Expenditures

-397,000.00USD

YoY

-70.81%

Last updated:

Capital Expenditures (CapEx) of Athersys is 2022 -397,000.00 USD. Capital Expenditures (CapEx) of Athersys was 2021 -1.36 M USD. It decreases by -70.81% higher compared to the previous year.

The Athersys Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2015
-130,000.00 USD
Jan 1, 2016
-1.71 M USD
Jan 1, 2017
-290,000.00 USD
Jan 1, 2018
-1.53 M USD
Jan 1, 2019
-579,000.00 USD
Jan 1, 2020
-1.16 M USD
Jan 1, 2021
-1.36 M USD
Jan 1, 2022
-397,000.00 USD
The Athersys Capital Expenditures history
YEARCapital ExpendituresYoY
-397,000.00USD-70.81%
-1.36 MUSD+17.04%
-1.16 MUSD+100.69%
-579,000.00USD-62.16%
-1.53 MUSD+427.59%
-290,000.00USD-83.04%
-1.71 MUSD+1,215.38%
-130,000.00USD-56.67%
-300,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Athersys Stock analysis

What does Athersys do? Athersys, Inc. generates revenue through the development and commercialization of its MultiStem (invimestrocel) cell therapy, an allogeneic stem cell product candidate derived from adult bone marrow. The company focuses on late-stage clinical development for critical care, neurological conditions, inflammatory disorders, pulmonary conditions, and cardiovascular disease. Its lead product, MultiStem, is currently in Phase III clinical trials for ischemic stroke under the MASTERS-2 study. Athersys targets medical institutions and healthcare providers seeking innovative treatments for unmet medical needs in multiple disease areas. The company's primary product, MultiStem, is manufactured from human stem cells obtained from adult bone marrow and alternative tissue sources. It is designed to address conditions including critical care indications, neurological disorders, inflammatory and immune disorders, pulmonary conditions, and cardiovascular disease. Athersys conducts Phase III trials for ischemic stroke treatment, aiming to secure regulatory approval for broader market access. Revenue streams are expected to emerge post-approval through therapeutic product sales to hospitals and clinics. Athersys, Inc. operates in the biotechnology sector with a focus on regenerative medicine, leveraging its MultiStem platform to address unmet medical needs. The company's clinical development strategy centers on late-stage trials for ischemic stroke and other conditions, targeting healthcare providers and medical institutions as key customers. Commercialization of MultiStem will likely involve partnerships with healthcare systems for treatment protocols and patient access. Athersys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athersys stock

Capital Expenditures (CapEx) of Athersys is -397,000.00 USD in 2022.

Capital Expenditures (CapEx) of Athersys changed from -1.36 M USD to -397,000.00 USD, representing a -70.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Athersys since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Athersys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Athersys

All Key Metrics — Athersys